Evaluation of orvepitant in an exploratory open-label clinical study in chronic treatment-refractory cough
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Orvepitant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Acronyms VOLCANO-1
- Sponsors NeRRe Therapeutics
- 24 May 2017 Primary endpoint (change in objective daytime cough frequency at Week 4 compared to Baseline) has been met, as per the results presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 13 Jun 2016 Status changed from active, no longer recruiting to completed.